Polychemotherapy with trastuzumab and pertuzumab in patients with HER2-positive BC is often associated with significant toxicity, and there is increasing interest in de-escalation strategies using techniques that induce a positive immune response in the tumor microenvironment in combination with HER2-targeted antibodies [84]. Here, ERBB2 is linked to breast cancer.